We thought that the World Cup was a timely icon for this blog series. This will be a blog series because there are so many reasons why we are the best aptamer company.
What are they?
- You own the aptamers, no royalties.
- Innovative NEOMER aptamer selection platform
- Improved aptamer performance in matrices
- Lower cost for multiple targets
- FRELEX selection platform for small molecules
- Focus on product concept applications
- Electrochemical detection
- Fluorescent switch
- qPCR
- Meta-analysis of selected structures
- Rational, intelligent identification of candidate sequences for all aptamer solutions to every problem.
NeoVentures has always been the thought leader in aptamer development. We have doubled down on this in the last year developing the NEOMER selection platform and the meta-analysis of aptamer structures. These breakthroughs overcome specific difficulties that have constrained the commercialization of aptamers previously.
Follow this series to learn more about why you should choose NeoVentures for your aptamer discovery and application needs.
Ready to get started? Contact us now.
Credit photo by Rhett Lewis
Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases.
Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures.
